This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Stocks in play: HLS Therapeutics Inc.

Baystreet.ca - Baystreet - Fri May 15, 9:17AM CDT

Announces its financial results for the three months ended March 31, 2026. All amounts are in thousands of United States dollars unless otherwise stated. Q1 2026 revenue was $12.9 million, Adjusted EBITDA was $3.5 million and cash from operations was $6.4 million, compared to $12.6 million, $3.8 million and $3.5 million, respectively. HLS Therapeutics Inc. shares T.HLS are trading unchanged at $4.67.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).